Tricyclo Ring System Patents (Class 514/662)
-
Publication number: 20130231391Abstract: The present invention relates to adamantane derivatives that are active as antiviral and anti-microbial agents; antiviral or antibacterial compositions comprising adamantane derivatives or pharmaceutically acceptable salts thereof; and methods of preventing or treating viral or bacterial infections in mammalian hosts through the administration of adamantine derivatives or their salts or pharmaceutical compositions comprising the same. In particular, viral infections prevented or treated by the methods of the present invention may include, but are not limited to, those caused by arenavirus or one or more pox viruses, such as vaccinia and/or variola.Type: ApplicationFiled: February 15, 2013Publication date: September 5, 2013Applicant: VYMED CORPORATIONInventor: B. Vithal SHETTY
-
Patent number: 8501816Abstract: Memantine compositions and methods of use are described herein. In some embodiments, the compositions comprise memantine and an absorption enhancer, or memantine and an elimination enhancer, or memantine and an absorption enhancer and an elimination enhancer.Type: GrantFiled: October 12, 2011Date of Patent: August 6, 2013Assignee: Cerecor, Inc.Inventors: Blake Paterson, Mark Ginski, Brendan Canning
-
Publication number: 20130165527Abstract: Compositions and methods for administering memantine to a subject are provided. In particular, a solid pharmaceutical composition in a unit dosage form for once daily oral administration is provided. The compositions comprises an extended release formulation of 22.5 mg to 33.75 mg memantine, or a pharmaceutically acceptable salt thereof, wherein administration of a dose of the composition to a human subject provides a mean plasma memantine concentration profile characterized by a change in memantine concentration as a function of time (dC/dT) that is less than 50% of the dC/dT provided by the same quantity of an immediate release form of memantine, determined in a time period between 0 hours to 6 hours after administration of memantine, and wherein dC/dT is measured in a single-dose human PK study. Methods of treating dementia, in particular Alzheimer's diseases, using the compositions are provided.Type: ApplicationFiled: January 28, 2013Publication date: June 27, 2013Applicant: ADAMAS PHARMACEUTICALS, INC.Inventor: ADAMAS PHARMACEUTICALS, INC.
-
Publication number: 20130131006Abstract: The present invention relates to a method for inhibiting the induction of cell death by inhibiting the synthesis or secretion of AGE-albumin in cells of the mononuclear phagocyte system, to an AGE-albumin synthesis inhibitor, and to a pharmaceutical composition comprising the AGE-albumin synthesis inhibitor for preventing or treating degenerative disease and autoimmune disease. The AGE-albumin of the present invention is synthesized and secreted in human microglia or human macrophages in an Alzheimer's model, stroke model, Parkinson's disease model and rheumatoid arthritis model. The AGE-albumin synthesis and secretion are caused by oxidative stress. The expression of RAGE increases in first-order human neurons or cartilage cells to which AGE-albumin is administered, whereupon a MAPK signaling pathway is activated and the expression of Bax increases to induce an increase in calcium in mitochondria, thus finally inducing cell death.Type: ApplicationFiled: April 28, 2011Publication date: May 23, 2013Applicant: Gachon University of Industry-Academic Cooperation FoundationInventors: Bong Hee Lee, Kyung Hee Byun
-
Publication number: 20130115249Abstract: The osmotic devices of the present invention contain a unitary core comprising a salt of amantadine and an osmotic salt, wherein the two salts have an ion in common. The release rate of the amantadine is a sigmoidal release. The osmotic device includes a semipermeable membrane having a controlled porosity that can be adapted as needed to cooperate with the osmotic salt in providing a predetermined drug release profile. The osmotic salt need not be coated and it is in admixture with the amantadine salt. The osmotic device further includes a drug-containing coat external to the semipermeable membrane. The osmotic device can include one or more additional drugs in the core and/or the drug-containing coat.Type: ApplicationFiled: July 18, 2012Publication date: May 9, 2013Applicant: OSMOTICA KERESKEDELMI ES SZOLGALTATO KFTInventors: Juan A. VERGEZ, Joaquina FAOUR, Ana C. PASTINI, Guido S. BIGATTI, Glenn A. MEYER, Ethel C. FELEDER, Marcelo A. RICCI, Marcelo A. COPPARI, Marcelo F. BEFUMO
-
Patent number: 8426472Abstract: The invention provides methods and compositions for administering an NMDA receptor antagonist (e.g., memantine) to a subject.Type: GrantFiled: October 28, 2011Date of Patent: April 23, 2013Assignee: Adamas Pharmaceuticals, Inc.Inventors: Gregory T. Went, Timothy J. Fultz, Seth Porter, Laurence R. Meyerson, Timothy S. Burkoth
-
Publication number: 20130072553Abstract: This invention relates to the drugs, derivatives and analogs containing adamantane structures of new indication applications of anti-tumor. The invention also relates to above compounds to treat tumors and other diseases with FIG. 1. These drugs, derivatives and analogs are generated by the modification of the parent or fragment structures and formation of pharmaceutically acceptable salts, complex salts or prodrug. The drugs, derivatives and analogs as described are administered alone or together with at least one known anti-tumor and immune chemotherapeutic agent including treatment of viral, bacterial and fungal diseases, neurological diseases, endocrine system diseases, and immune system diseases.Type: ApplicationFiled: December 25, 2009Publication date: March 21, 2013Inventor: Lifeng Xu
-
Publication number: 20130011474Abstract: The present invention provides immediate release and modified release oral dosage forms. Specifically, the invention provides modified and immediate release pharmaceutical dosage forms containing memantine that exhibit an enhanced release profile and provide reliable absorption. The dosage forms may be used to treat mild, moderate or severe Alzheimer's disease or neuropathic pain.Type: ApplicationFiled: September 14, 2012Publication date: January 10, 2013Applicant: FOREST LABORATORIES HOLDINGS LTD.Inventors: Mahendra G. DEDHIYA, Suneel K. RASTOGI, Anil CHHETTRY, Narasimhan MANI, Antonia PERICLOU, Niranjan Rao
-
Publication number: 20130012593Abstract: The present invention provides pharmaceutical compositions given once daily containing at least one therapeutically active ingredient selected from the group consisting of memantine and a pharmaceutically acceptable salt of memantine, and a pharmaceutically acceptable polymeric matrix carrier. The dosage forms of the invention sustain the release of the therapeutically active agent from about 4 to about 24 hours when said dosage form is exposed to aqueous solutions, following entry of said form into a use environment, wherein said dosage form has a dissolution rate of more than about 80% after passage of about 6 hours to about 12 hours following said entry into said use environment.Type: ApplicationFiled: September 14, 2012Publication date: January 10, 2013Applicant: Forest Laboratories Holdings Ltd.Inventors: Suneel K. Rastogi, Niranjan Rao, Antonia Periclou, Wattanaporn Abramowitz, Mahendra G. Dedhiya, Shashank Mahashabde
-
Publication number: 20120309785Abstract: The subject invention provides materials and methods for treating neurodegenerative diseases. In one embodiment of the invention, a cysteamine compound is administered to a patient to treat Parkinson's Disease and/or complications associated with Parkinson's Disease. In another embodiment, a cysteamine compound is administered to a patient to prevent the onset of Parkinson's Disease in an at-risk patient and/or treat or prevent the onset of Parkinson's Disease-associated symptoms.Type: ApplicationFiled: December 5, 2011Publication date: December 6, 2012Inventor: Bill Piu Chan
-
Publication number: 20120295886Abstract: The present disclosure provides compounds having affinity for the M2 proton channel, useful for the treatment of viral infections such as influenza, which are of the Formula (I): wherein R1, R2, and Y are as defined herein. Methods of preparing the compounds, pharmaceutical compositions containing the compounds, and methods of using the compounds in the treatment of viral infections such as influenza are also provided.Type: ApplicationFiled: May 18, 2012Publication date: November 22, 2012Applicant: INFLUMEDIX, INC.Inventors: Jizhou Wang, Xiaodong Fan, Lidia Cristian
-
Publication number: 20120263779Abstract: A drug delivery system (DDS) comprised of segmented biodegradable implants sized and suitable for implantation in an ocular region or site and methods for treating ocular conditions. The segmented implants provide an extended release of an active agent at a therapeutically effective amount for a period of time between 50 days and one year, or longer, and permit the DDS to have segments that possess individual and different drug release characteristics.Type: ApplicationFiled: June 13, 2012Publication date: October 18, 2012Inventors: Robert T. Lyons, James A. Burke, Michael R. Robinson
-
Publication number: 20120264829Abstract: The invention provides methods for administering memantine to a subject. Memantine in an extended release form containing 22.5 to 30 mg memantine or a pharmaceutically acceptable salt is administered to a patient suffering from a neurological condition, such as Alzheimer's disease, Parkinson's disease or dementia. The extended release form achieves particular pharmacokinetic criteria such as change in plasma concentration of memantine over time and ratio of maximum memantine plasma concentration to mean memantine plasma concentration.Type: ApplicationFiled: June 28, 2012Publication date: October 18, 2012Applicant: Adamas Pharmaceuticals, Inc. a Delaware CorporationInventors: Gregory T. Went, Timothy J. Fultz, Laurence R. Meyerson
-
Publication number: 20120258176Abstract: The invention discloses particulate complexes composed of chitosan, poly-glutamic acid, and at least one bioactive agent, wherein equal moles of the positively charged chitosan and the negatively charged poly-glutamic acid substrate form an electrostatic network enabling improved loading the bioactive agent.Type: ApplicationFiled: May 7, 2012Publication date: October 11, 2012Inventors: Hsing-Wen Sung, Zi-Xian Liao, Shu-Fen Peng, Hosheng Tu
-
Publication number: 20120252820Abstract: Methods of identifying compounds that potentiate the activity of antifungal agents, potentiators identified by these methods, and methods of using potentiators to treat fungal infections are disclosed.Type: ApplicationFiled: April 22, 2009Publication date: October 4, 2012Applicant: NORTHEASTERN UNIVERSITYInventors: Kim Lewis, Michael David Lafleur
-
Publication number: 20120207809Abstract: Methods and systems are described for a rapid and sustainable change in the pigment melanin content of melanocytes of the iris stroma, thereby to change the color of the eye. Also described are compositions for lightening or darkening the pigmented tissues or treating a pigmented tissue disease.Type: ApplicationFiled: November 30, 2011Publication date: August 16, 2012Inventor: Kambiz Thomas Moazed
-
Publication number: 20120201889Abstract: The present invention provides immediate release and modified release oral dosage forms. Specifically, the invention provides modified and immediate release pharmaceutical dosage forms containing memantine that exhibit an enhanced release profile and provide reliable absorption. The dosage forms may be used to treat mild, moderate or severe Alzheimer's disease or neuropathic pain.Type: ApplicationFiled: February 15, 2012Publication date: August 9, 2012Applicant: Forest Laboratories Holdings Ltd.Inventors: Mahendra G. Dedhiya, Suneel K. Rastogi, Anil Chhettry, Narasimhan Mani, Antonia Periclou, Niranjan Rao
-
Publication number: 20120183527Abstract: The present invention provides improved immunoaffinity methods for detecting high avidity anti-amyloid antibodies present in a biological sample. In other aspects, the present invention provides methods for diagnosing diseases associated with amyloid proteins. Also provided by the present invention are methods for identifying candidates likely to respond to treatment comprising administration of an immunoglobulin preparation.Type: ApplicationFiled: January 18, 2011Publication date: July 19, 2012Applicants: Baxter International Inc., Cornell University, Baxter Healthcare S.A.Inventors: Norman RELKIN, Paul Szabo
-
Publication number: 20120157537Abstract: Aminocyclohexane and aminoalkylcyclohexane compounds, which are systemically-active as NMDA receptor antagonists, are effective in inhibiting abnormal hyperphosphorylation of microtubule associated protein tau, method of treating disorders resulting from or associated with abnormal hyperphosphorylation of microtubule associated protein tau, and pharmaceutical compositions comprising the same.Type: ApplicationFiled: June 10, 2011Publication date: June 21, 2012Inventors: Khalid Iqbal, Inge Grundke-Iqbal
-
Publication number: 20120121729Abstract: Memantine compositions and methods of use are described herein. In some embodiments, the compositions comprise memantine and an absorption enhancer, or memantine and an elimination enhancer, or memantine and an absorption enhancer and an elimination enhancer.Type: ApplicationFiled: October 12, 2011Publication date: May 17, 2012Inventors: Blake PATERSON, Mark Ginski, Brendan Canning
-
Publication number: 20120114604Abstract: The present invention relates to co-administering a Hepatitis C virus NS3/4A protease inhibitor and a cytochrome P450 monooxygenase inhibitor. The combination acts by interfering with the life cycle of the hepatitis C virus and is therefore useful as an antiviral therapy. As such, the combination may be used for treating or preventing Hepatitis C infections in patients. The invention also relates to compositions comprising the combination of inhibitors. The invention also relates to kits and pharmaceutical packs comprising a Hepatitis C virus NS3/4A protease inhibitor and a cytochrome P450 monooxygenase inhibitor. The invention also relates to processes for preparing these compositions, combinations, kits, and packs.Type: ApplicationFiled: January 23, 2012Publication date: May 10, 2012Applicant: Vertex Pharmaceuticals IncorporatedInventors: Roger Tung, Gurudatt Chandorkar, Robert Perni
-
Publication number: 20120093738Abstract: The present invention relates to taste-masked oral formulations of influenza antivirals. The taste-masked pharmaceutical formulations for oral administration comprise one or more influenza antivirals, at least one taste-masking agent and at least one pharmaceutically acceptable excipient. Further, the taste-masked influenza antiviral formulations of the present invention are provided in the form of dispersible tablets, effervescent tablets, orally disintegrating tablets, chewable tablets, bite-dispersion tablets or the like, wherein the bitter taste of influenza antivirals is masked thereby providing palatable formulations.Type: ApplicationFiled: June 10, 2010Publication date: April 19, 2012Applicant: Rubicon Research Private LimitedInventors: Pratibha Sudhir Pilgaonkar, Maharukh Tehmasp Rustomjee, Anilkumar Surendrakumar Gandhi
-
Publication number: 20120076848Abstract: Methods and systems are described for a rapid and sustainable change in the pigment melanin content of melanocytes of the iris stroma, thereby to change the color of the eye. Also described are nanoparticle compositions for lightening the pigmented tissues or treating a pigmented tissue related disease.Type: ApplicationFiled: July 21, 2010Publication date: March 29, 2012Inventor: Kambiz Thomas Moazed
-
Publication number: 20120058182Abstract: The invention provides methods and compositions for administering an NMDA receptor antagonist (e.g., memantine) to a subject.Type: ApplicationFiled: April 9, 2010Publication date: March 8, 2012Applicant: Adamas Pharmaceuticals, Inc.Inventors: Gregory T. Went, Timothy J. Fultz, Seth Porter, Laurence R. Meyerson, Timothy S. Burkoth
-
Publication number: 20120045508Abstract: The invention provides methods and compositions for administering an NMDA receptor antagonist (e.g., memantine) to a subject.Type: ApplicationFiled: April 9, 2010Publication date: February 23, 2012Applicant: Adamas Pharmaceuticals, Inc.Inventors: Gregory T. Went, Timothy J. Fultz, Seth Porter, Laurence R. Meyerson, Timothy S. Burkoth
-
Publication number: 20120040993Abstract: Multifunctional compounds are provided, comprising two or more functional moieties selected from: (i) a moiety that imparts an iron chelator function; (ii) a moiety that imparts a neuroprotective function; (iii) a moiety that imparts combined antiapoptotic, neuroprotective and/or neurorestorative functions; (iv) a moiety that imparts brain MAO inhibition, preferably with little or no MAO inhibition in liver and small intestine; (v) a moiety that imparts cholinesterase inhibitory function; and (vi) a moiety that imparts an N-methyl-D-aspartic acid receptor (NMDAR) inhibition, and pharmaceutically acceptable salts and optical isomers thereof. The multifunctional compounds are useful in the treatment or prevention of diseases, disorders or conditions that can be prevented and/or treated by iron chelation therapy, and/or neuroprotection and/or neurorestoration, and/or apoptosis inhibition and/or MAO inhibition and/or cholinesterase inhibition and/or NMADR inhibition.Type: ApplicationFiled: January 31, 2010Publication date: February 16, 2012Applicants: TECHNION RESEARCH AND DEVELOPMENT FOUNDATION LTD., YEDA RESEARCH AND DEVELOPMENT CO., LTD.Inventors: Moussa B. H. Youdim, Mati Fridkin, Hailin Zheng
-
Publication number: 20120004318Abstract: The present invention provides pharmaceutical compositions given once daily containing at least one therapeutically active ingredient selected from the group consisting of memantine and a pharmaceutically acceptable salt of memantine, and a pharmaceutically acceptable polymeric matrix carrier. The dosage forms of the invention sustain the release of the therapeutically active agent from about 4 to about 24 hours when said dosage form is exposed to aqueous solutions. following entry of said form into a use environment, wherein said dosage form has a dissolution rate of more than about 80% after passage of about 6 hours to about 12 hours following said entry into said use environment.Type: ApplicationFiled: September 15, 2011Publication date: January 5, 2012Applicant: FOREST LABORATORIES HOLDINGS LTD.Inventors: Suneel K. Rastogi, Niranjan Rao, Antonia Periclou, Wattanaporn Abramowitz, Mahendra G. Dedhiya, Shashank Mahashabde
-
Publication number: 20110313372Abstract: The invention relates to transdermal therapeutic systems (TTS) which include, as active ingredient, the NMDA receptor antagonist memantine or one of its physiologically compatible salts. The TTSs can be produced and used for treating diseases of the central nervous system.Type: ApplicationFiled: June 17, 2011Publication date: December 22, 2011Inventors: René EIFLER, Michael Horstmann, Regine Kaufmann, Patrick Mohr
-
Publication number: 20110312894Abstract: The present invention relates to methods of diagnosing, treating and prognosing mental disorders, such as Alzheimer's Disease. In one embodiment, the present invention provides a method of treating Alzheimer's Disease by inhibiting dysfunctional signaling of ?7 nAChRs in the medial septum region of an individual.Type: ApplicationFiled: January 28, 2010Publication date: December 22, 2011Applicant: CATHOLIC HEALTHCARE WESTInventor: Jie Wu
-
Patent number: 8067394Abstract: This invention describes novel tricyclic-bis-enone derivatives (TBEs), such as TBE-31, TBE-34, TBE-45 and water-soluble TBEs. The methods of preparing these compounds are also disclosed. The inventors demonstrate the ability of these new TBEs to inhibit proliferation of human myeloma cells, inhibit the induction of iNOS in cells stimulated with interferon-?, induce heme oxygenase-1 (HO-1), induce CD11b expression—a leukemia differentiation marker, inhibit proliferation of leukemia cells, induce apoptosis in human lung cancer, and induce apoptosis in other cancerous cells. The TBEs of this invention are expected to be useful agents for the treatment and prevention of many diseases, including cancer, neurological disorders, inflammation, and pathologies involving oxidative stress.Type: GrantFiled: May 10, 2010Date of Patent: November 29, 2011Assignee: Trustees of Dartmouth CollegeInventors: Tadashi Honda, Chitra Sundararajan, Gordon W. Gribble, Michael B. Sporn, Karen T. Liby
-
Publication number: 20110288111Abstract: Provided are compounds that are capable of modulating the activity of the influenza A virus via interaction with the M2 transmembrane protein. Also provided are methods for treating an influenza A-affected disease state or infection comprising administering a composition comprising one or more compounds that have been identified as being capable of interaction with the M2 protein.Type: ApplicationFiled: August 21, 2009Publication date: November 24, 2011Applicant: The Trustees of the University of PennsylvaniaInventors: William F. DeGrado, Jun Wang
-
Publication number: 20110280909Abstract: Methods and systems are described for a rapid and sustainable change in the pigment melanin content of melanocytes of the iris stroma, thereby to change the color of the eye. Also described are nanoparticle compositions for lightening the pigmented tissues or treating a pigmented tissue related disease.Type: ApplicationFiled: January 29, 2010Publication date: November 17, 2011Inventor: Kambiz Thomas Moazed
-
Publication number: 20110281912Abstract: The present invention relates to an oral dispersible tablet comprising at least one filler selected from sugars and sugar alcohols, and microcrystalline cellulose.Type: ApplicationFiled: December 18, 2009Publication date: November 17, 2011Applicant: RATIOPHARM GMBHInventors: Sven Winter, Max-Werner Scheiwe
-
Publication number: 20110217261Abstract: The present invention relates to pharmaceutical agents administered to a subject either in combination or in series for the treatment of a flaviviridae viral infection, for example, hepatitis C virus (HCV), wherein treatment comprises administering a compound effective to inhibit the function of the HCV NS5A protein and an additional compound or combinations of compounds having anti-HCV activity.Type: ApplicationFiled: August 5, 2010Publication date: September 8, 2011Inventors: Yat Sun Or, Christopher M. Owens, Bradley B. Brasher, Yao-Ling Qiu, Lijuan Jiang
-
Publication number: 20110189273Abstract: Methods of nighttime administration of amantadine to reduce sleep disturbances in patient undergoing treatment with amantadine are described, as well as compositions of extended release amantadine that are suitable for nighttime administration.Type: ApplicationFiled: December 2, 2010Publication date: August 4, 2011Applicant: Adamas Pharmaceuticals, Inc.Inventors: Gregory T. Went, Gayatri Sathyan, Kavita Vermani, Gangadhara Ganapati, Michael Coffee, Efraim Shek, Ashok Katdare
-
Publication number: 20110183942Abstract: A method is disclosed for inhibiting the build-up of amyloid plaques in the brain of a patient with at least one risk factor for, or a diagnosis of, Alzheimer's Disease by administering to the patient an amount of one or more compounds effective to inhibit the phosphorylative activity of eEF2K, thereby inhibiting amyloid plaque deposition.Type: ApplicationFiled: July 15, 2009Publication date: July 28, 2011Applicants: UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY, JOHNS HOPKINS UNIVERSITYInventors: Paul Worley, Sungjin Park, Alexey G. Ryazanov
-
Patent number: 7981930Abstract: Kits comprising an M2 inhibitor selected from amantadine and rimantadine; ribavirin, and a neuraminidase inhibitor (NAi) in an amount that is antivirally effective in the combination, an oral dosage form containing 75-250 mg of the M2 inhibitor, an oral dosage form comprising 100-400 mg of ribavirin and a neuraminidase inhibitor are provided for the treatment of influenza. Some embodiments of the kits comprise an oral dosage form containing 75-250 mg of the M2 inhibitor, an oral dosage form comprising 100-400 mg of ribavirin, and a neuraminidase inhibitor.Type: GrantFiled: February 29, 2008Date of Patent: July 19, 2011Assignee: Adamas Pharmaceuticals, Inc.Inventors: Jack Nguyen, Gregory T. Went, Paul Spence, Timothy J. Fultz, David Chernoff, Terry L. Burkoth, Rowan Chapman, Mickey S. Urdea
-
Publication number: 20110118307Abstract: Methods and compositions for treating disease caused by infectious agents, particularly tuberculosis. In particular, methods and compositions comprising substituted ethylene diamines for the treatment of infectious diseases are provided. In one embodiment, these methods and compositions are used for the treatment of mycobacterial infections, including, but not limited to, tuberculosis.Type: ApplicationFiled: November 11, 2010Publication date: May 19, 2011Inventors: Marina Nikolaevna PROTOPOPOVA, Richard Edward Lee, Richard Allan Slayden, Clifton E. Barry, III, Elena Bogatcheva, Leo Einck
-
Publication number: 20110065762Abstract: The present invention relates, in part, to methods of treatment, prevention, and inhibition of viral disorders. In one aspect, the present invention relates to inhibition of the M2 proton channel of influenza viruses (e.g. influenza A virus) and other similar viroporins (e.g., VP24 of Ebola and Marburg viruses; and NS3 protein of Bluetongue). The present invention further relates, inter alia, to compounds which have been shown to possess antiviral activity, in particular, inhibiting the M2 proton channel of influenza viruses.Type: ApplicationFiled: September 13, 2010Publication date: March 17, 2011Inventors: Jizhou Wang, Xiaodong Fan, Lidia Cristian
-
Publication number: 20110064804Abstract: The present invention provides novel methods and compositions for the treatment and prevention of CNS-related conditions. One of the CNS-related conditions treated by the methods and compositions of the invention is Alzheimer's disease.Type: ApplicationFiled: April 9, 2010Publication date: March 17, 2011Applicant: Adamas Pharmaceuticals, Inc.Inventors: Gregory T. Went, Timothy J. Fultz
-
Publication number: 20110065766Abstract: The present invention relates, in part, to methods of treatment, prevention, and inhibition of viral disorders. In one aspect, the present invention relates to inhibition of the M2 proton channel of influenza viruses (e.g. influenza A virus) and other similar viroporins (e.g., VP24 of Ebola and Marburg viruses; and NS3 protein of Bluetongue). The present invention further relates, inter alia, to compounds which have been shown to possess antiviral activity, in particular, inhibiting the M2 proton channel of influenza viruses.Type: ApplicationFiled: September 13, 2010Publication date: March 17, 2011Inventors: Jizhou Wang, Xiaodong Fan, Lidia Cristian
-
Publication number: 20110059141Abstract: Disclosed is a percutaneous absorption preparation which enables the stable administration of an antidementia drug over a long period of time. More particularly, the percutaneous absorption preparation of the antidementia drug which is used as a plaster on skin comprises at least an adherent layer, an intermediate membrane, and a drug reservoir layer sequentially from the side which is plastered on skin, wherein the drug reservoir layer comprises at least an antidementia drug, an aminated polymer, a polyhydric alcohol, and one or more carboxylic acid esters, the intermediate membrane enables the controlled permeation of the antidementia drug into the side of skin, the adherent layer enables the plastering of the percutaneous absorption preparation on skin, and is permeable to the antidementia drug.Type: ApplicationFiled: November 17, 2010Publication date: March 10, 2011Inventor: Takeshi Ito
-
Publication number: 20110059886Abstract: The present invention relates to inhibiting the activity of non-genotype 1 hepatitis C virus (HCV) NS3-NS4A protease activity. More particularly, the invention relates to inhibiting the activity of the protease from HCV genotype-2 or HCV genotype-3. The methods of the invention emply inhibitors that act by interfering with the life cycle of the HCV and are also useful as antiviral agents. The invention further relates to compositions comprising such compounds either for ex vivo use or for administration to a patient suffering from genotype-2 or genotype-3 HCV infection. The invention also relates to methods of treating an HCV infection in a patient by administering a composition comprising a compound of this invention.Type: ApplicationFiled: November 22, 2010Publication date: March 10, 2011Applicant: VERTEX PHARMACEUTICALS INCORPORATEDInventors: Chao Lin, William P. Taylor
-
Publication number: 20110053981Abstract: The invention provides methods for treating and/or preventing Alzheimer's disease, psychiatric illnesses, encephalitis, meningitis, fetal alcohol syndrome, Karsakoff's syndrome, anoxic brain injury, cardiopulmonary resuscitation injuries, diabetes, Sjogren's syndrome, mental retardation, developmental delay, menopause, strokes, macular degeneration, neuronal loss associated with macular degeneration, sleep disorders, severe Alzheimer's disease, jet lag, post-traumatic stress disorder, anxiety disorders, panic attacks, obsessive-compulsive disorder, amnesia, and other disorders by administering to a patient in need thereof at least one cholinesterase inhibitor. The invention also provides novel pharmaceutical compositions that can be administered to the eyes or to the nose of patients. In one embodiment, the cholinesterase inhibitor is donepezil, a stereoisomer thereof and/or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: October 12, 2010Publication date: March 3, 2011Applicant: Eisai R&D Management Co., Ltd.Inventors: John Ieni, Raymond Pratt
-
Publication number: 20110046232Abstract: Orally dissolving formulations, e.g., tablets (ODTs) and films (ODFs) comprising memantine and methods of treating conditions, including childhood behavioral disorders and Alzheimer's disease, by administering orally dissolving formulations are provided. The orally dissolving formulations of the present invention may be used to treat various conditions, but is particularly suited to treat childhood behavioral disorders, such as autistic spectrum disorders or combined type Attention-Deficit/Hyperactivity Disorder (ADHD) and also to treat elderly patients suffering from Alzheimer's disease.Type: ApplicationFiled: September 23, 2010Publication date: February 24, 2011Applicant: FOREST LABORATORIES HOLDINGS LTD.Inventors: Shashank Mahashabde, Mahendra G. Dedhiya, Anil Chhettry, Ranajoy Sarkar
-
Publication number: 20110045074Abstract: A matrix type sustained-release preparation and a manufacturing method therefor are provided wherein dissolution with low pH dependence of a basic drug or a salt thereof at the early stage of dissolution can be ensured in a dissolution test, and wherein as the dissolution test proceeds, a ratio of a dissolution rate of the basic drug or the salt thereof in an acidic test solution to a dissolution rate of the basic drug or the salt thereof in a neutral test solution (dissolution rate in the acidic test solution/dissolution rate in the neutral test solution) decreases with dissolution time at the late stage of dissolution, as compared to the early stage of dissolution. According to the present invention, the matrix type sustained-release preparation contains a basic drug or a salt thereof and at least one enteric polymer, in which solubility of the basic drug or the salt thereof in a 0.1 N hydrochloric acid solution and a neutral aqueous solution, pH 6.0 is higher than in a basic aqueous solution, pH 8.0.Type: ApplicationFiled: October 22, 2010Publication date: February 24, 2011Applicant: Eisai R&D Management Co., Ltd.Inventors: Yosuke Ueki, Satoshi Fujioka
-
Publication number: 20110039942Abstract: The present invention relates to a titration package for providing at least one pharmaceutical composition in at least two different dosages. The titration package comprises at least two sets. Each set comprises at least three individually addressable regions. Each addressable region preferably comprises or is represented by a pharmaceutical composition, preferably a tablet. The dosage of the pharmaceutical composition is the same within each of the at least two sets (“common dosage”), while the dosages of the pharmaceutical compositions are different for one of the at least two sets compared to at least one other of the at least two sets. The arrangement of the at least two sets is not a matrix-like arrangement.Type: ApplicationFiled: January 14, 2009Publication date: February 17, 2011Applicant: Merz Pharma GmbH & Co. KGaAInventor: Diego M. Arbaiza Taurel
-
Publication number: 20110014202Abstract: The present invention relates to a method for diagnosing neuroendocrine cancers via detecting the presence of N-methyl D-asparate-associated (NMDA) glutamate receptors type 1 and/or type 2. Methods for preventing and treating neuroendocrine cancers are also disclosed.Type: ApplicationFiled: September 7, 2010Publication date: January 20, 2011Inventor: William G. North
-
Publication number: 20110008465Abstract: A pharmaceutical composition comprising a water insoluble sesquiterpene, one or more antioxidants and one or more solubilizers selected from the group consisting of an oil, PEG400, a derivative of castor oil and ethylene oxide, and polysorbate 80, and methods of use thereof.Type: ApplicationFiled: June 2, 2008Publication date: January 13, 2011Inventors: Jean Legault, Andre Pichette, Serge Lavoie
-
Publication number: 20110009363Abstract: This invention describes novel tricyclic-bis-enone derivatives (TBEs), such as TBE-31, TBE-34, TBE-45 and water-soluble TBEs. The methods of preparing these compounds are also disclosed. The inventors demonstrate the ability of these new TBEs to inhibit proliferation of human myeloma cells, inhibit the induction of iNOS in cells stimulated with interferon-?, induce heme oxygenase-1 (HO-1), induce CD11b expression—a leukemia differentiation marker, inhibit proliferation of leukemia cells, induce apoptosis in human lung cancer, and induce apoptosis in other cancerous cells. The TBEs of this invention are expected to be useful agents for the treatment and prevention of many diseases, including cancer, neurological disorders, inflammation, and pathologies involving oxidative stress.Type: ApplicationFiled: May 10, 2010Publication date: January 13, 2011Inventors: Tadashi Honda, Chitra Sundararajan, Gordon W. Gribble, Michael B. Sporn, Karen T. Liby